Impact of Edaravone on Short-Term and Long-Term Motor Recovery After Acute Ischemic Stroke in Patients Who Did Not Receive Thrombolytic or Endovascular Treatment

IF 1.1 3区医学 Q2 CLINICAL NEUROLOGY

Acta Neurologica Scandinavica Pub Date : 2026-06-10 DOI:10.1155/ane/5558787

Mehdi Kazemloo, Fatemeh Shamlouie, Majid Ebrahimi Nejad, Nahid Hosseini Nejad Mir, Danyal Yarahmadi

{"title":"Impact of Edaravone on Short-Term and Long-Term Motor Recovery After Acute Ischemic Stroke in Patients Who Did Not Receive Thrombolytic or Endovascular Treatment","authors":"Mehdi Kazemloo, Fatemeh Shamlouie, Majid Ebrahimi Nejad, Nahid Hosseini Nejad Mir, Danyal Yarahmadi","doi":"10.1155/ane/5558787","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Background</h3>\n \n <p>Many patients with acute ischemic stroke (AIS) are ineligible for thrombolysis. Evidence on edaravone in this population is limited.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study is a retrospective cohort study on adults with imaging-confirmed AIS admitted to Shohada-e-Ashayer Hospital (March 2022–February 2023) who did not receive thrombolysis. Patients who received intravenous edaravone within the first day of onset plus standard care were compared with standard care alone. Motor strength was assessed with the Medical Research Council (MRC) scale (0–5) at baseline, 1 week, and 3 months. The primary outcome was 3-month motor function; secondary outcomes included ≥ 2-point improvement from baseline.</p>\n </section>\n \n <section>\n \n <h3> Result</h3>\n \n <p>Among 160 patients (<i>n</i> = 80 edaravone; <i>n</i> = 80 control), baseline characteristics were similar. At 3 months, the intervention group had higher MRC grades and a higher proportion achieving ≥ 2-grade improvement; 1-week differences were not significant.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In AIS patients ineligible for thrombolysis, edaravone was associated with better 3-month motor strength; no significant between-group differences were observed at 1 week. Prospective randomized trials are warranted.</p>\n </section>\n </div>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/5558787","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neurologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ane/5558787","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Many patients with acute ischemic stroke (AIS) are ineligible for thrombolysis. Evidence on edaravone in this population is limited.

Methods

This study is a retrospective cohort study on adults with imaging-confirmed AIS admitted to Shohada-e-Ashayer Hospital (March 2022–February 2023) who did not receive thrombolysis. Patients who received intravenous edaravone within the first day of onset plus standard care were compared with standard care alone. Motor strength was assessed with the Medical Research Council (MRC) scale (0–5) at baseline, 1 week, and 3 months. The primary outcome was 3-month motor function; secondary outcomes included ≥ 2-point improvement from baseline.

Result

Among 160 patients (n = 80 edaravone; n = 80 control), baseline characteristics were similar. At 3 months, the intervention group had higher MRC grades and a higher proportion achieving ≥ 2-grade improvement; 1-week differences were not significant.

Conclusions

In AIS patients ineligible for thrombolysis, edaravone was associated with better 3-month motor strength; no significant between-group differences were observed at 1 week. Prospective randomized trials are warranted.

Abstract Image

查看原文本刊更多论文

依达拉奉对未接受溶栓或血管内治疗的急性缺血性卒中患者短期和长期运动恢复的影响

背景：许多急性缺血性卒中（AIS）患者不适合溶栓治疗。依达拉奉在这一人群中的应用证据有限。方法本研究是一项回顾性队列研究，研究对象为Shohada-e-Ashayer医院（2022年3月至2023年2月）未接受溶栓治疗的影像学确诊AIS成人。在发病第一天内接受静脉注射依达拉奉加标准治疗的患者与单独接受标准治疗的患者进行比较。运动强度在基线、1周和3个月时按照医学研究委员会（MRC）评分（0-5）进行评估。主要终点是3个月的运动功能；次要结局包括较基线改善≥2点。结果160例患者（依达拉奉组80例，对照组80例），基线特征相似。3个月时，干预组MRC评分较高，改善≥2级的比例较高；1周差异不显著。结论：在不适合溶栓治疗的AIS患者中，依达拉奉与3个月运动强度改善相关；第1周各组间无显著差异。前瞻性随机试验是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Neurologica Scandinavica 医学-临床神经学

CiteScore

6.70

自引率

2.90%

发文量

161

审稿时长

4-8 weeks

期刊介绍： Acta Neurologica Scandinavica aims to publish manuscripts of a high scientific quality representing original clinical, diagnostic or experimental work in neuroscience. The journal''s scope is to act as an international forum for the dissemination of information advancing the science or practice of this subject area. Papers in English will be welcomed, especially those which bring new knowledge and observations from the application of therapies or techniques in the combating of a broad spectrum of neurological disease and neurodegenerative disorders. Relevant articles on the basic neurosciences will be published where they extend present understanding of such disorders. Priority will be given to review of topical subjects. Papers requiring rapid publication because of their significance and timeliness will be included as ''Clinical commentaries'' not exceeding two printed pages, as will ''Clinical commentaries'' of sufficient general interest. Debate within the speciality is encouraged in the form of ''Letters to the editor''. All submitted manuscripts falling within the overall scope of the journal will be assessed by suitably qualified referees.